Validation of Optimum ROI Size for I-FP-CIT SPECT Imaging Using a 3D Mathematical Cylinder Phantom

Overview

Journal Asia Ocean J Nucl Med Biol

Specialty Nuclear Medicine

Date 2018 Jul 13

PMID 29998147

Authors

Hideo Onishi

Takayuki Sakai

Osamu Shiromoto

Hizuru Amijima

Affiliations

Soon will be listed here.

Abstract

Objectives: The partial volume effect (PVE) of single-photon emission computed tomography (SPECT) on corpus striatum imaging is caused by the underestimation of specific binding ratio (SBR). A large ROI (region of interest) set using the Southampton method is independent of PVE for SBR. The present study aimed to determine the optimal ROI size with contrast and SBR for striatum images and validate the Southampton method using a three-dimensional mathematical cylinder (3D-MAC) phantom.

Methods: We used ROIs sizes of 27, 36, 44, 51, 61, 68, and 76 mm for targets with diameters 40, 20, and 10 mm on reference and processed images reconstructed using the 3D-MAC phantom. Contrast values and SBR were compared with the theoretical values to obtain the optimal ROI size.

Results: The contrast values in the ROI with diameters of 51 (target: 40 mm in diameter) and 44 (target: 20 mm in diameter) mm matched the theoretical values. However, this value did not correspond with the 10-mm-diameter target. The SBR matched the theoretical value with an ROI of > 44 mm in the 20-mm-diameter target; but, it was under- and overestimated under any other conditions.

Conclusion: These results suggested that an ROI should be 2-4 folds larger than the target size without PVE, and that the Southampton method was remarkably accurate.

References

Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brucke T . [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm (Vienna). 1999; 105(10-12):1213-28. DOI: 10.1007/s007020050124. View

Soret M, Koulibaly P, Darcourt J, Buvat I . Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification. Eur J Nucl Med Mol Imaging. 2006; 33(9):1062-72. DOI: 10.1007/s00259-005-0003-4. View

Tossici-Bolt L, Dickson J, Sera T, Booij J, Asenbaun-Nan S, Bagnara M . [I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. EJNMMI Phys. 2017; 4(1):8. PMC: 5272851. DOI: 10.1186/s40658-017-0175-6. View

Booij J, Habraken J, Bergmans P, Tissingh G, Winogrodzka A, Wolters E . Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med. 1998; 39(11):1879-84. View

Tossici-Bolt L, Hoffmann S, Kemp P, Mehta R, Fleming J . Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging. 2006; 33(12):1491-9. DOI: 10.1007/s00259-006-0155-x. View

Buchert R, Kluge A, Tossici-Bolt L, Dickson J, Bronzel M, Lange C . Reduction in camera-specific variability in [(123)I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls. Eur J Nucl Med Mol Imaging. 2016; 43(7):1323-36. DOI: 10.1007/s00259-016-3309-5. View

Benamer T, Patterson J, Grosset D, Booij J, De Bruin K, van Royen E . Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000; 15(3):503-10. View

Booij J, Tissingh G, Boer G, Speelman J, Stoof J, Janssen A . [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997; 62(2):133-40. PMC: 486723. DOI: 10.1136/jnnp.62.2.133. View

Albert N, Unterrainer M, Diemling M, Xiong G, Bartenstein P, Koch W . Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. Eur J Nucl Med Mol Imaging. 2016; 43(7):1315-22. DOI: 10.1007/s00259-015-3304-2. View

10.

McKeith I, OBrien J, Walker Z, Tatsch K, Booij J, Darcourt J . Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007; 6(4):305-13. DOI: 10.1016/S1474-4422(07)70057-1. View

11.

Dickson J, Tossici-Bolt L, Sera T, Booij J, Ziebell M, Morbelli S . The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [I]FP-CIT SPECT imaging. EJNMMI Res. 2017; 7(1):10. PMC: 5265228. DOI: 10.1186/s13550-016-0253-0. View

12.

Soret M, Koulibaly P, Darcourt J, Hapdey S, Buvat I . Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT. J Nucl Med. 2003; 44(7):1184-93. View

13.

Onishi H, Motomura N, Takahashi M, Yanagisawa M, Ogawa K . A 3-dimensional mathematic cylinder phantom for the evaluation of the fundamental performance of SPECT. J Nucl Med Technol. 2010; 38(1):42-8. DOI: 10.2967/jnmt.108.061192. View

14.

Tossici-Bolt L, Dickson J, Sera T, de Nijs R, Bagnara M, Jonsson C . Calibration of gamma camera systems for a multicentre European ¹²³I-FP-CIT SPECT normal database. Eur J Nucl Med Mol Imaging. 2011; 38(8):1529-40. DOI: 10.1007/s00259-011-1801-5. View

15.

David R, Koulibaly M, Benoit M, Garcia R, Caci H, Darcourt J . Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases A SPECT study with partial volume effect correction. Clin Neurol Neurosurg. 2007; 110(1):19-24. DOI: 10.1016/j.clineuro.2007.08.007. View

16.

Narita Y, Eberl S, Iida H, Hutton B, Braun M, Nakamura T . Monte Carlo and experimental evaluation of accuracy and noise properties of two scatter correction methods for SPECT. Phys Med Biol. 1996; 41(11):2481-96. DOI: 10.1088/0031-9155/41/11/017. View

17.

Fleming J, Bolt L, Stratford J, Kemp P . The specific uptake size index for quantifying radiopharmaceutical uptake. Phys Med Biol. 2004; 49(14):N227-34. DOI: 10.1088/0031-9155/49/14/n03. View

18.

Brucke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C . Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl. 1997; 50:9-24. View